Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of Clinical Investigation

• Publication date

  1994-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1172/JCI117259PMID 8200986PMCID PMC294465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Isolation and characterization of thrombin-activated human factor VIII.

  1994cited by this paper
• A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2.

  1993cited by this paper
• Intrinsic pathway activation of factor X and its activation peptide-deficient derivative, factor Xdes-143-191.

  1992cited by this paper
• The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa. A fluorescence study.

  1992cited by this paper
• Epitope mapping of human factor VIII inhibitor antibodies by site‐directed mutagenesis of a factor VIII polypeptide

  1992cited by this paper
• Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain.

  1992cited by this paper
• Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles.

  1992cited by this paper
• A Soluble Recombinant Factor VIII Fragment Containing the A2 Domain Binds to Some Human Anti-Factor VIII Antibodies that Are not Detected by Immunoblotting

  1992cited by this paper
• Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog.

  1991cited by this paper
• Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit.

  1991cited by this paper
• Prothrombinase complex assembly. Contributions of protein-protein and protein-membrane interactions toward complex formation.

  1990cited by this paper
• pH-dependent denaturation of thrombin-activated porcine factor VIII.

  1990cited by this paper
• Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine.

  1990cited by this paper
• Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization.

  1989cited by this paper
• Subunit structure of thrombin-activated porcine factor VIII.

  1989cited by this paper
• Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.

  1989cited by this paper
• Identification of a F.VIII epitope recognized by a human hemophilic inhibitor.

  1989cited by this paper
• Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli.

  1988cited by this paper
• Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.

  1988cited by this paper
• Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders.

  1988cited by this paper
• Complete cDNA and derived amino acid sequence of human factor V.

  1987cited by this paper
• Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments.

  1985cited by this paper
• Structure of human factor VIII

  1984cited by this paper
• Stabilization of thrombin-activated porcine factor VIII:C by factor IXa phospholipid.

  1984cited by this paper
• Molecular cloning of a cDNA encoding human antihaemophilic factor

  1984cited by this paper
• Discoidin I-membrane interactions II. Discoidin I binds to and agglutinates negatively charged phospholipid vesicles

  1982cited by this paper
• The role of phospholipid and factor VIIIa in the activation of bovine factor X.

  1981cited by this paper
• Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity.

  1981cited by this paper
• Regulation of plasminogen activator secretion in mouse peritoneal macrophages. I. - Role of serum studied by a new spectrophotometric assay for plasminogen activators.

  1979cited by this paper
• Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

  1978cited by this paper
• A simple method for the preparation of homogeneous phospholipid vesicles.

  1977cited by this paper
• Free energy diagrams and concentration profiles for enzyme-catalyzed reactions.

  1976cited by this paper
• A More Uniform Measurement of Factor VIII Inhibitors

  1975cited by this paper
• Letter: A more uniform measurement of factor VIII inhibitors.

  1975cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• Reaction Sequence of Blood Coagulation

  1967cited by this paper

• Factor IXa and Factor X Influence Factor VIIIa Stability and Inactivation Mechanisms In Vitro and In Vivo.

  2025cites this paper
• Mice possess a more limited natural anti-human Factor VIII antibody repertoire than humans that is produced disproportionately by marginal zone B cells.

  2023cites this paper
• Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies.

  2023cites this paper
• Structural Characterization of Factor VIII-Inhibitor Complexes and Factor VIII Lipid Binding Mechanics

  2022cites this paper
• Structural and Mutational Characterization of the Blood Coagulation Factor VIII C Domain Lipid Binding Interface

  2021cites this paper
• Activated Protein C has a Regulatory Role in Factor VIII Function.

  2021cites this paper
• Molecular Mechanisms of Inhibitor Development in Hemophilia

  2020cites this paper
• Exosites expedite blood coagulation

  2020cites this paper
• Exosite binding drives substrate affinity for the activation of coagulation factor X by the intrinsic Xase complex

  2020influential citation
• Factor VIII

  2018cites this paper
• Factor VIII inhibitors: Advances in basic and translational science

  2017cites this paper
• Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti‐factor VIII antibodies in hemophilia A mice

  2016cites this paper
• High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

  2016cites this paper
• Computer‐predicted peptides that mimic discontinuous epitopes on the A2 domain of factor VIII

  2015cites this paper
• Treatment Options for Acquired Hemophilia

  2014cites this paper
• THROMBOSIS AND HEMOSTASIS The diversity of the immune response to the A 2 domain of human factor VIII

  2013influential citation
• VIII molecules antibody plasmas using multiply-substituted hybrid human/porcine factor Reduction of the antigenicity of factor VIII toward complex inhibitory

  2013cites this paper
• Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

  2013cites this paper
• The diversity of the immune response to the A2 domain of human factor VIII.

  2013cites this paper
• Inhibitory antibodies in hemophilia A

  2012cites this paper
• Novel function of coagulation factor Xa : conversion into a clot-dissolving cofactor

  2011cites this paper
• Use of affinity‐directed liquid chromatography‐mass spectrometry to map the epitopes of a factor VIII inhibitor antibody fraction

  2011cites this paper
• HERPESVIRUS MEDIATED ACTIVATION OF COAGULATION AND FIBRINOLYTIC PROTEINS

  2011cites this paper
• Involvement of the contact phase and intrinsic pathway in herpes simplex virus‐initiated plasma coagulation

  2010cites this paper
• Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

  2010cites this paper
• Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A

  2010cites this paper
• Management of Haemophilia A-Inhibitor Patients: Clinical and Regulatory Perspectives

  2009cites this paper
• B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses

  2009cites this paper
• Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab.

  2008cites this paper
• The heparin-binding exosite is critical to allosteric activation of factor IXa in the intrinsic tenase complex: the role of arginine 165 and factor X.

  2007cites this paper
• The humoral response to human factor VIII in hemophilia A mice

  2007cites this paper
• Epitope mapping factor VIII A2 domain by affinity‐directed mass spectrometry: residues 497–510 and 584–593 comprise a discontinuous epitope for the monoclonal antibody R8B12

  2006cites this paper
• Factor VIII Structure and Function

  2006cites this paper
• Anti-factor VIII antibodies

  2005cites this paper
• Mutating factor VIII: lessons from structure to function.

  2005cites this paper
• Pathogenic antibodies to coagulation factors. Part one: Factor VIII and Factor IX

  2004cites this paper
• T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects

  2004cites this paper
• Clustered basic residues within segment 484–510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation

  2004cites this paper
• Activation of factor VIII and mechanisms of cofactor action.

  2004cites this paper
• Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor

  2003cites this paper
• Pathophysiology of inhibitors to factor VIII in patients with haemophilia A

  2002cites this paper
• The Evidence behind Inhibitor Treatment with Porcine Factor VIII

  2002cites this paper
• The concept of idiotypic vaccination against factor VIII inhibitors in haemophilia A

  2002cites this paper
• Human Factor VIII Inhibitor Alloantibodies with a C2 Epitope Inhibit Factor Xa-catalyzed Factor VIII Activation: A new Anti-factor VIII Inhibitory Mechanism

  2002cites this paper
• Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex.

  2002cites this paper
• Molecular Characterization of the Immune Response to Factor VIII

  2002cites this paper
• Von Willebrand Factor Modulates Factor VIII Immunogenicity: Comparative Study of Different Factor VIII Concentrates in a Haemophilia A Mouse Model

  2002cites this paper
• Mechanism of the Immune Response to Human Factor VIII in Murine Hemophilia A

  2001cites this paper
• Factor VIII inhibitors.

  2001cites this paper
• Factor IXa:Factor VIIIa Interaction

  2001cites this paper
• Antibody studies of factor VIII inhibitor in a case with Waldenström's macroglobulinemia

  2000cites this paper
• In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice.

  2000cites this paper
• Prevention and treatment of factor VIII inhibitors in murine hemophilia A.

  2000cites this paper
• Partial Correction of Murine Hemophilia A with Neo-Antigenic Murine Factor VIII

  2000cites this paper
• Properties of Anti-Factor VIII Inhibitor Antibodies in Hemophilia A Patients

  2000cites this paper
• Natural Antibodies to Factor VIII

  2000cites this paper
• Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules.

  2000cites this paper
• Immune Tolerance Therapy for Haemophilia

  2000cites this paper
• Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain.

  2000cites this paper
• Role of the Low Density Lipoprotein-related Protein Receptor in Mediation of Factor VIII Catabolism*

  1999cites this paper
• Regulation of Factor VIIIa in the Intrinsic Factor Xase

  1999cites this paper
• Characterization of Factor VIII B-Cell Inhibitory Epitopes

  1999cites this paper
• Epitope Specificity and Inactivation Mechanisms of Factor VIII Inhibitor Antibodies

  1999cites this paper
• Inhibitor Antibody Development and T Cell Response to Human Factor VIII in Murine Hemophilia A

  1999cites this paper
• Human Inhibitor Antibodies Specific for the Factor VIII A2 Domain Disrupt the Interaction between the Subunit and Factor IXa*

  1999cites this paper
• A human alloantibody interferes with binding of factor IXa to the factor VIII light chain.

  1998cites this paper
• Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII.

  1998cites this paper
• Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor.

  1998cites this paper
• Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy.

  1998cites this paper
• The A2 Subunit of Factor VIIIa Modulates the Active Site of Factor IXa*

  1998cites this paper
• Dominant C2 Domain Epitope Specificity of Inhibitor Antibodies Elicited by a Heat Pasteurized Product, Factor VIII CPS-P, in Previously Treated Hemophilia A Patients without Inhibitors

  1998cites this paper
• Some human inhibitor antibodies interfere with factor VIII binding to factor IX.

  1998cites this paper
• Localization of a Factor X Interactive Site in the A1 Subunit of Factor VIIIa*

  1997cites this paper
• Analysis of the Human Factor VIII A2 Inhibitor Epitope by Alanine Scanning Mutagenesis*

  1997cites this paper
• Analysis of Free Factor VIII Antigen in Commercial Factor VIII Concentrates

  1997cites this paper
• Subunit structure and function of porcine factor Xa-activated factor VIII.

  1997cites this paper
• Factor VIII Inhibitors

  1997cites this paper
• Interferon‐γ secretion defects in haemophilia A patients receiving highly purified plasma‐derived or recombinant factor VIII

  1996cites this paper
• Activated Protein C-catalyzed Proteolysis of Factor VIIIa Alters Its Interactions within Factor Xase (*)

  1996cites this paper
• T Lymphocyte Proliferative Responses Induced by Recombinant Factor VIII in Hemophilia A Patients with Inhibitors

  1996cites this paper
• Slowed Release of Thrombin-cleaved Factor VIII from von Willebrand Factor by a Monoclonal and a Human Antibody Is a Novel Mechanism for Factor VIII Inhibition*

  1996cites this paper
• Human Anti‐Factor VIII Antibodies: Epitope Localization and Inhibitory Function

  1996cites this paper
• Structure and function of Factor VIII.

  1995cites this paper
• Immunoblot cross-reactivity of factor VIII inhibitors with porcine factor VIII.

  1995cites this paper
• Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII (*)

  1995cites this paper
• Progress in the Understanding of Factor VIII Inhibitors

  1994cites this paper
• Factor VIII Structure and Function

  1993cites this paper